1P-ETH-LAD (1-propionyl-6-ethyl-6-nor-lysergic acid diethylamide) is a synthetic psychedelic of the lysergamide family structurally derived from ETH-LAD. It is the N1-propionyl ester of ETH-LAD — meaning a propionyl group is attached to the nitrogen at position 1 of the lysergamide core. Like several other 1-acyl lysergamide designer drugs, 1P-ETH-LAD is widely believed to function as a prodrug that is rapidly cleaved by plasma esterases into the parent compound ETH-LAD following ingestion.
The subjective character of 1P-ETH-LAD closely resembles ETH-LAD but is consistently reported by experienced users to feel somewhat warmer, more visually elaborate, and more emotionally engaging than LSD at comparable doses. Community reports highlight that the onset is often slower than LSD (60–90 minutes) and that the experience tends toward the immersive and philosophical rather than the stimulating and analytical. The ethyl modification at the 6-position of the lysergamide nucleus appears to produce a more enveloping, sensory-rich experience compared to the diethyl amide substitution found in LSD.
1P-ETH-LAD emerged in the research chemical market around 2015, sold on blotter tabs. It gained rapid popularity among experienced psychedelic users who had encountered ETH-LAD and sought a legal analog with similar properties. Community experience with microdosing protocols emphasizes that 1P-ETH-LAD at sub-threshold doses (5–15 μg) can provide subtle mood and focus enhancement, though some users note residual visual disturbances at doses that would be completely sub-perceptual for LSD.
As with all lysergamide research chemicals, the long-term safety profile of 1P-ETH-LAD has not been formally studied. The risks are presumed to be similar to LSD and ETH-LAD but cannot be confirmed. Individuals with a personal or family history of psychosis or bipolar disorder should avoid this compound entirely. Testing with an Ehrlich reagent (purple/violet reaction) is essential before use to rule out more dangerous adulterants.
Safety at a Glance
High Risk- Dose information for 1P-ETH-LAD is extrapolated from community experience, not clinical data:
- Threshold: 25–50 μg
- Toxicity: Acute Toxicity No formal toxicological data exist for 1P-ETH-LAD in humans. Based on its structural relationship to E...
- Overdose risk: Fatal overdose from 1P-ETH-LAD alone, at doses within the typical recreational range, is extremel...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
oral
Duration
oral
Total: 6 hrs – 12 hrsHow It Feels
Almost immediately there is a sense that something unusual is happening in the body. Within twenty minutes of ingestion a heavy, electric warmth spreads through the abdomen and limbs. The body load of 1P-ETH-LAD announces itself early and insistently: a tightness in the stomach, a buzzing tension in the muscles, a sensation that the body is being subtly reorganized from the inside. This is not comfortable in the conventional sense, but neither is it straightforwardly unpleasant. It is simply intense.
The visual onset is rapid and dramatic. By the forty-minute mark the visual field is already richly ornamented. Surfaces fracture into tessellated geometries, colors shift through impossible spectra, and depth perception becomes deeply unreliable. Flat walls appear to curve and breathe, faces become alien topographies, and closed-eye space opens into vast architectural vistas that dwarf anything you can construct with imagination alone. The visual intensity of this substance frequently surpasses what people report from LSD at comparable doses.
The headspace is where things become truly distinctive. There is a quality of confusion that permeates the cognitive experience, not stupefying confusion but a slippery, labyrinthine quality to thought. Ideas begin and then fork unexpectedly; you lose the thread of sentences midway through; the passage of time becomes profoundly distorted, sometimes seeming to loop or stutter. This can be disorienting and occasionally frightening, but it can also produce moments of startling insight when familiar concepts are encountered from entirely unfamiliar angles. Emotional responses are amplified and volatile, swinging between wonder and unease with little warning.
The experience is shorter than LSD, typically winding down significantly by the six-hour mark. The offset is characterized by a gradual loosening of the visual intensity and a slow return of cognitive linearity. The body load diminishes but often leaves a residual soreness, as though you have been clenching muscles you did not know you had. The afterglow can carry a quality of relief and quiet amazement, a sense of having navigated something genuinely challenging and emerged with new terrain mapped inside your mind.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(13)
- Bodily control enhancement— Bodily control enhancement is the subjective feeling of improved physical precision, coordination, a...
- Body load— A diffuse, heavy physical discomfort involving tension, pressure, and malaise in the torso and limbs...
- Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
- Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
- Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
- Pupil dilation— A visible enlargement of the pupil diameter (mydriasis) that can range from subtle widening to drama...
- Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
- Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
- Serotonin syndrome— Serotonin syndrome is a potentially fatal medical emergency caused by excessive serotonergic activit...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
- Teeth grinding— An involuntary clenching and rhythmic grinding of the jaw muscles, known clinically as bruxism, that...
- Temperature regulation disruption— Impaired thermoregulation causing unpredictable fluctuations between feeling hot and cold, with risk...
- Vasoconstriction— A narrowing of blood vessels throughout the body that produces sensations of cold extremities, tingl...
Tactile(1)
- Tactile enhancement— The sense of touch becomes dramatically heightened, making physical contact feel intensely pleasurab...
Cognitive & Perceptual Effects
Visual(16)
- After images— A visual phenomenon in which a faint, ghostly imprint of a previously viewed image persists in the v...
- Colour enhancement— An intensification of the brightness, vividness, and saturation of colors in the external environmen...
- Colour shifting— The visual experience of colors on objects and surfaces cycling through continuous, fluid transforma...
- Depth perception distortions— Alterations in how the distance of objects within the visual field is perceived, causing layers of s...
- Diffraction— The experience of seeing rainbow-like spectrums of color and prismatic halos embedded within bright ...
- Drifting— The visual experience of perceiving stationary objects, textures, and surfaces as appearing to flow,...
- Geometry— The experience of perceiving complex, ever-shifting geometric patterns superimposed over the visual ...
- Internal hallucination— Vivid, detailed visual experiences perceived within an imagined mental landscape that can only be se...
- Pattern recognition enhancement— An increased ability and tendency to perceive meaningful patterns, faces, and images within ambiguou...
- Perspective hallucination— A hallucinatory phenomenon in which the observer's visual perspective shifts from the normal first-p...
- Scenery slicing— The visual field fractures into distinct, cleanly cut sections that slowly drift apart from their or...
- Settings, sceneries, and landscapes— The perceived environment in which hallucinatory experiences take place, ranging from recognizable l...
- Symmetrical texture repetition— Textures appear to mirror and tessellate across surfaces in intricate, self-similar symmetrical patt...
- Tracers— Moving objects leave visible trails of varying length and opacity behind them, similar to long-expos...
- Transformations— Objects and scenery undergo perceived visual metamorphosis, smoothly shapeshifting into other recogn...
- Visual acuity enhancement— Vision becomes sharper and more defined than normal, as though a slightly blurry lens has been broug...
Cognitive(18)
- Analysis enhancement— A perceived improvement in one's ability to logically deconstruct concepts, recognize patterns, and ...
- Anxiety— Intense feelings of apprehension, worry, and dread that can range from a subtle background unease to...
- Conceptual thinking— A shift in the nature of thought from verbal, linear sentence structures to intuitive, non-linguisti...
- Confusion— An impairment of abstract thinking marked by a persistent inability to grasp or comprehend concepts ...
- Deja vu— Intense, often prolonged sensation of having already experienced the current moment, common with psy...
- Delusion— A delusion is a fixed, false belief that is held with unshakeable certainty and is impervious to con...
- Immersion enhancement— A heightened capacity to become fully absorbed and engrossed in external media such as music, films,...
- Introspection— An enhanced state of self-reflective awareness in which one feels drawn to examine their own thought...
- Memory suppression— A dose-dependent inhibition of one's ability to access and utilize short-term and long-term memory, ...
- Motivation enhancement— A heightened sense of drive, ambition, and willingness to accomplish tasks, making productive effort...
- Novelty enhancement— A feeling of increased fascination, awe, and childlike wonder attributed to everyday concepts, objec...
- Paranoia— Irrational suspicion and belief that others are watching, plotting against, or intending harm toward...
- Personal bias suppression— A decrease in the personal, cultural, and cognitive biases through which one normally filters their ...
- Psychosis— Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — char...
- Thought acceleration— The experience of thoughts occurring at a dramatically increased rate, as if the mind has been shift...
- Thought loops— Becoming trapped in a repeating cycle of thoughts, actions, and emotions that loops every few second...
- Time distortion— Subjective perception of time becomes dramatically altered — minutes may feel like hours, or hours p...
- Wakefulness— An increased ability to stay awake and alert without the desire to sleep. Distinct from stimulation ...
Multi-sensory(1)
- Scenarios and plots— Scenarios and plots are the narrative structures that emerge within hallucinatory states — coherent ...
Transpersonal(3)
- Ego death— A profound dissolution of the sense of self in which personal identity, memories, and the boundary b...
- Existential self-realization— A sudden, visceral realization of the profound significance and improbability of one's own existence...
- Unity and interconnectedness— A profound sense that identity extends beyond the self to encompass other people, nature, or all of ...
Pharmacology
Mechanism of Action
1P-ETH-LAD is strongly believed to act primarily as a prodrug for ETH-LAD, with the N1-propionyl moiety being cleaved by plasma and tissue esterases shortly after administration. The resulting ETH-LAD then acts as a partial agonist at serotonin 5-HT2A receptors, particularly in cortical layer V pyramidal neurons of the prefrontal cortex — the primary pharmacological mechanism shared by all classical psychedelics. Activation of 5-HT2A receptors disrupts the brain's normal predictive-coding hierarchy, allowing unfiltered sensory and associative content to enter conscious awareness, producing the characteristic perceptual and cognitive alterations of the lysergamide class.
Receptor Targets
Like LSD and related lysergamides, 1P-ETH-LAD (via its ETH-LAD active form) likely engages a broad receptor profile beyond 5-HT2A:
- 5-HT2A receptors — principal target; partial agonist; responsible for perceptual and cognitive effects
- 5-HT1A receptors — partial agonist; may modulate the overall tone of the experience, contributing to introspective quality
- 5-HT2C receptors — agonist activity; implicated in anxiogenic potential at higher doses
- Dopamine D2/D3 receptors — moderate affinity; contributes to stimulation, mood, and mental acceleration
- α1-adrenergic receptors — contributes to mydriasis and mild sympathomimetic effects
The ethyl substitution at the 6-position (distinguishing ETH-LAD from LSD) appears to modify binding kinetics and/or receptor signaling bias relative to LSD, likely accounting for the subjective differences users describe — greater visual complexity, warmer emotional tone, and somewhat more sedative quality.
Pharmacokinetics
Prodrug hydrolysis of the N1-propionyl group is expected to occur rapidly in the gut and bloodstream, analogous to the 1P-LSD → LSD conversion demonstrated in human pharmacokinetic studies. The onset of effects (60–90 minutes) is consistent with a conversion step preceding receptor engagement. Peak effects are typically reached at 2–4 hours. Total duration is approximately 8–12 hours, with a protracted afterglow of several additional hours. Metabolism is likely hepatic, with the usual lysergamide metabolic pathways producing hydroxylated and glucuronidated derivatives. No formal human pharmacokinetic data are available.
Tolerance
Cross-tolerance with LSD and other serotonergic psychedelics is expected and well-reported in the community. Functional tolerance develops within 24–48 hours and reverses over approximately 5–7 days. Repeated use within this window produces dramatically diminished effects.
Detection Methods
Urine Detection
1P-ETH-LAD and its metabolites are not targeted by standard immunoassay-based urine drug screens. Because lysergamides are active at microgram doses, the absolute quantity of drug and metabolite present in biological samples is extremely low, making detection inherently difficult. Specialized urine assays using liquid chromatography-tandem mass spectrometry (LC-MS/MS) can identify lysergamide metabolites within approximately 24 to 72 hours after ingestion, though this window is shorter than most other drug classes due to rapid metabolism and renal clearance.
Blood and Serum Detection
Blood detection windows for 1P-ETH-LAD are narrow. Plasma concentrations peak within 1 to 3 hours of oral administration and fall below detectable thresholds within 6 to 12 hours for most analytical methods. LC-MS/MS can extend this window modestly, but serum testing for lysergamides is rarely performed outside of forensic or research contexts due to the specialized equipment required and the very low concentrations involved.
Standard Drug Panel Inclusion
1P-ETH-LAD is NOT included on standard 5-panel, 10-panel, or 12-panel drug screens. These panels test for amphetamines, cannabinoids, cocaine metabolites, opiates, and PCP (with extended panels adding benzodiazepines, barbiturates, and similar classes). Lysergamides do not cross-react with any of these immunoassay targets. Detection requires a specific request for lysergamide testing, which is uncommon in workplace, probationary, or emergency department screening.
Confirmatory Methods
When lysergamide use is specifically suspected, confirmatory testing relies on LC-MS/MS or gas chromatography-mass spectrometry (GC-MS). LC-MS/MS is the preferred method due to its superior sensitivity at picogram-per-milliliter concentrations. Immunoassay-based LSD-specific screens exist but suffer from high false-negative rates with novel lysergamide analogs, as antibody cross-reactivity varies between compounds.
Reagent Testing (Harm Reduction)
For harm reduction identification, the Ehrlich reagent is the primary tool for 1P-ETH-LAD. A small sample placed on the reagent should produce a purple to violet color change, indicating the presence of an indole moiety characteristic of lysergamides. The Hofmann reagent provides a confirmatory blue to purple reaction. Importantly, the Marquis reagent shows no reaction or a faint olive discoloration with lysergamides, which helps distinguish them from other compound classes. A positive Ehrlich result does not confirm the specific lysergamide identity but does rule out NBOMe and NBOH compounds, which show no Ehrlich reaction. Using both Ehrlich and Hofmann reagents together provides greater confidence in lysergamide identification.
Interactions
| Substance | Status | Note |
|---|---|---|
| 3-FMA | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 4-MMC | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| 8-Chlorotheophylline | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Adrafinil | Caution | Increases anxiety, cardiovascular stress, and psychological intensity |
| Anandamide | Caution | Cannabis can unpredictably intensify psychedelic effects and increase anxiety |
| Cannabis | Uncertain | — |
| 1,3-Butanediol | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 25E-NBOH | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 2C-T | Low Risk & Synergy | Cross-tolerance exists; effects compound |
| 2C-T-2 | Low Risk & Synergy | Cross-tolerance exists; effects compound |
History
Origins
1P-ETH-LAD was first described and synthesized by the research chemical community in approximately 2015, following the template established by 1P-LSD. The goal was to produce a legally distinct analog of ETH-LAD at a time when ETH-LAD itself had been placed under analog act controls in several jurisdictions. The compound was developed building on Alexander Shulgin and Ann Shulgin's foundational work on lysergamides published in TiHKAL (1997), which described ETH-LAD and related compounds as part of a systematic exploration of lysergic acid derivatives.
Market History
1P-ETH-LAD appeared on research chemical vendor markets primarily in 2015–2018, sold on blotter tabs or as solutions. It gained popularity in psychedelic communities, particularly among users who had prior experience with ETH-LAD and valued its distinct character relative to LSD.
Legal Status
The regulatory status of 1P-ETH-LAD varies by jurisdiction. It is not scheduled under international drug conventions, but many countries have enacted blanket bans on novel psychoactive substances or have analog acts that may encompass it. In the United States, it may be subject to prosecution under the Federal Analogue Act. It has been specifically scheduled in the United Kingdom under the Psychoactive Substances Act 2016 and in several other European countries. Researchers and users should verify current local law before obtaining or possessing this compound.
Harm Reduction
Testing
Always test with an Ehrlich reagent before use. A genuine lysergamide produces a purple/violet reaction. No reaction indicates the absence of an indole compound. NBOMe compounds (which are far more toxic) do not react with Ehrlich. A Hofmann reagent provides additional confirmation. Given that 1P-ETH-LAD is a research chemical without regulated supply chains, adulteration risk is meaningful.
Dosing
Dose information for 1P-ETH-LAD is extrapolated from community experience, not clinical data:
- Threshold: 25–50 μg
- Light: 50–75 μg
- Common: 75–150 μg
- Strong: 150–250 μg
For first-time users or those unfamiliar with lysergamides, starting at 50–75 μg is strongly recommended. Community reports of microdosing suggest 5–15 μg on a Fadiman protocol (every third day), with notes that residual visual effects may persist at doses that would be fully sub-threshold for LSD.
Set and Setting
- Approach in a stable emotional state; do not use during periods of acute psychological stress
- Choose a familiar, comfortable environment where you feel safe and in control
- A trusted, sober trip-sitter is strongly recommended for first or high-dose experiences
- Community reports describe this compound as particularly immersive — nature settings are frequently cited as excellent, but urban or unfamiliar environments carry greater disorientation risk
Dangerous Combinations
- Lithium — Do not combine; seizure and cardiac event risk documented across lysergamide class
- MAOIs — Risk of serotonin syndrome
- Tramadol — Lowers seizure threshold; contraindicated
- Cannabis — Frequently and unpredictably amplifies intensity; a major contributor to difficult experiences
- Stimulants (amphetamines, cocaine) — Increases cardiovascular stress and psychological intensity
Emergency Protocol
- If a difficult experience occurs, change the environment: move rooms, go outside, change music
- Cold water on face, slow breathing, and physical contact with a trusted person are effective grounding techniques
- Benzodiazepines (diazepam 10–20 mg, or similar) reliably reduce lysergamide intensity without dangerous interaction — the standard harm reduction intervention
- If in physical danger or unresponsive, call emergency services; inform them of the substance taken
Toxicity & Safety
Acute Toxicity
No formal toxicological data exist for 1P-ETH-LAD in humans. Based on its structural relationship to ETH-LAD and LSD, acute toxicity is expected to be extremely low. No fatalities directly attributable to 1P-ETH-LAD pharmacological action have been reported. As with LSD, the principal risks are psychological rather than physiological.
Cardiovascular Effects
1P-ETH-LAD produces the sympathomimetic effects typical of lysergamides: mild tachycardia, modest blood pressure elevation, mydriasis, and peripheral vasoconstriction mediated via α-adrenergic activity. These are generally well tolerated in healthy individuals but pose meaningful risk for those with pre-existing cardiovascular conditions, hypertension, or arrhythmias. Community reports note that the cardiovascular stimulation is similar in magnitude to LSD and less pronounced than higher-stimulation research chemicals such as DOx compounds.
Psychological Risks
- Acute anxiety and panic — As with all lysergamides, overwhelming anxiety, paranoia, and panic are the primary adverse events. Risk scales steeply with dose. Community reports describe 1P-ETH-LAD's difficult experiences as particularly immersive and harder to reality-test than LSD.
- Psychosis induction — Absolute contraindication in personal or family history of schizophrenia, schizoaffective disorder, or bipolar I disorder.
- HPPD — Persistent visual disturbances following use have been reported by users, though prevalence is unknown. Risk is elevated by frequent use and high doses.
Contraindications
- Personal or family history of psychosis or bipolar disorder
- Current use of lithium, MAOIs, antipsychotics, or tramadol
- Pregnancy or breastfeeding
- Cardiovascular disease or uncontrolled hypertension
Overdose
No cases of overdose requiring medical intervention due to pharmacological toxicity alone have been reported. Extreme psychological distress is the most likely presentation. Benzodiazepines (e.g., diazepam 10–20 mg) are the first-line intervention for acute anxiety or psychological crisis.
Addiction Potential
not habit-forming
Overdose Information
Fatal overdose from 1P-ETH-LAD alone, at doses within the typical recreational range, is extremely unlikely based on the available evidence for classical psychedelics. The therapeutic index for most psychedelics is very wide.
However, psychological emergencies can occur and require appropriate response:
- Severe anxiety, panic, or psychotic episodes
- Dangerous behavior due to impaired reality testing
- Self-harm in the context of a distressing experience
Emergency management: If someone is experiencing a severe adverse reaction, move them to a calm, quiet environment. Speak reassuringly. Do not restrain unless there is immediate danger. Benzodiazepines (if available and the person is conscious and able to swallow) can reduce acute anxiety. If psychotic symptoms, self-harm risk, or medical distress is present, seek emergency medical attention.
Medical attention: Seek help immediately for seizures, extremely elevated body temperature, signs of serotonin syndrome (agitation, tremor, diarrhea, rapid heart rate), or if the substance consumed is uncertain.
Tolerance
| Full | almost immediately after ingestion |
| Half | 3 days |
| Zero | 7 days |
Cross-tolerances
Legal Status
It is unclear in many countries whether this compound is legal or not and one should take precaution by assuming it is illegal to avoid legal issues.
Canada: 1P-ETH-LAD is controlled as Schedule III substance under the Precursor Control Regulations of the Controlled Drugs and Substances Act.
Germany: 1P-ETH-LAD is controlled under the NpSG (New Psychoactive Substances Act) as of July 18, 2019. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
Switzerland: 1P-ETH-LAD can be considered a controlled substance as a defined derivative of Lysergic Acid under Verzeichnis E point 263. It is legal when used for scientific or industrial use.
Turkey:** 1P-ETH-LAD is a classed as drug and is illegal to possess, produce, supply, or import.
United States: 1P-ETH-LAD may be considered illegal in the U.S. under the Federal Analogue Act.
United Kingdom: It is illegal to produce, supply, or import this substance under the Psychoactive Substance Act, which came into effect on May 26, 2016..
Responsible use
Designer drug
Psychedelics
Prodrug
ETH-LAD
1P-ETH-LAD (Wikipedia)
1P-ETH-LAD (Isomer Design)
Discussion
The Small & Handy 1P-ETH-LAD Thread (Bluelight)
Experience Reports (1)
Tips (5)
Use a milligram scale to weigh 1P-ETH-LAD if it comes as a powder. Eyeballing doses of potent psychedelics is irresponsible. A quality 0.001g scale costs under $30 and could prevent a seriously overwhelming experience.
Clear your schedule for the full duration of 1P-ETH-LAD plus afterglow. Do not plan any obligations, driving, or important decisions for the day. Having a time pressure or commitment hanging over you adds unnecessary anxiety.
Do not combine 1P-ETH-LAD with lithium (seizure risk), tramadol (seizure/serotonin syndrome risk), or cannabis at higher doses unless very experienced. Cannabis dramatically intensifies and can destabilize a psychedelic experience.
People with a personal or family history of psychotic disorders (schizophrenia, bipolar type I) should avoid 1P-ETH-LAD and other psychedelics. These substances can trigger or exacerbate psychotic episodes in predisposed individuals.
Psychedelic tolerance builds rapidly. Wait at least 1-2 weeks between uses of 1P-ETH-LAD for full tolerance reset. Taking the same dose the next day would require roughly double the amount for comparable effects.
See Also
References (4)
- Psilocybin produces substantial and sustained decreases in depression and anxiety — Griffiths et al. Journal of Psychopharmacology (2016)paper
- Neural correlates of the LSD experience revealed by multimodal neuroimaging — Carhart-Harris et al. PNAS (2016)paper
- 1P-ETH-LAD - TripSit Factsheet
TripSit factsheet for 1P-ETH-LAD
tripsit - 1P-ETH-LAD - Wikipedia
Wikipedia article on 1P-ETH-LAD
wikipedia